Will Google Stock Double by 2030?
If you bought Alphabet (NASDAQ: GOOGL) when Gmail launched in…
Sell
41
RXRX Quote, Financials, Valuation and Earnings
Last price:
$5.03
Seasonality move
:
-7.05%
Day range:
$4.98 - $5.48
52-week range:
$3.79 - $12.36
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
26.57x
P/B ratio:
2.19x
Volume:
46.6M
Avg. volume:
27.6M
1-year change:
-33.6%
Market cap:
$2B
Revenue:
$58.5M
EPS (TTM):
-$1.77
Analysts' Opinion
-
Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $7.14, Recursion Pharmaceuticals has an estimated upside of 42.01% from its current price of $5.03.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $5.03.
Fair Value
-
According to the consensus of 7 analysts, Recursion Pharmaceuticals has 42.01% upside to fair value with a price target of $7.14 per share.
RXRX vs. S&P 500
-
Over the past 5 trading days, Recursion Pharmaceuticals has underperformed the S&P 500 by -3.33% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Recursion Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Recursion Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Recursion Pharmaceuticals reported revenues of $14.8M.
Earnings Growth
-
Recursion Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Recursion Pharmaceuticals reported earnings per share of -$0.50.
Enterprise value:
1.6B
EV / Invested capital:
--
Price / LTM sales:
26.57x
EV / EBIT:
--
EV / Revenue:
26.24x
PEG ratio (5yr expected):
-0.31x
EV / Free cash flow:
-3.91x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$3.9M
Return On Assets:
-59.7%
Net Income Margin (TTM):
-960.92%
Return On Equity:
-82.61%
Return On Invested Capital:
-80%
Operating Margin:
-1291.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $46.5M | $45.2M | $59.8M | $13.5M | $14.8M | |
| Gross Profit | -$6.4M | $3.9M | $3.9M | $2.3M | -$7M | |
| Operating Income | -$259.6M | -$376.5M | -$574M | -$96.3M | -$191.4M | |
| EBITDA | -$236M | -$330.8M | -$524.8M | -$84.8M | -$182.8M | |
| Diluted EPS | -$1.38 | -$1.62 | -$1.77 | -$0.39 | -$0.50 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $221.8M | $619.5M | $492.1M | $343.6M | $584.1M | |
| Total Assets | $271.9M | $734.3M | $627.4M | $557.8M | $1.3B | |
| Current Liabilities | $26.9M | $85.7M | $92.2M | $73.9M | $142M | |
| Total Liabilities | $505M | $240.8M | $197.2M | $156.7M | $371.3M | |
| Total Equity | -$233M | $493.6M | $430.2M | $401.2M | $933.9M | |
| Total Debt | $12.5M | $702K | $1.8M | $1.1M | $25M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$234.2M | -$316.8M | -$388.8M | -$102.3M | -$132M | |
| Cash From Investing | $44.6M | -$11.5M | $259.4M | -$6.7M | -$7.3M | |
| Cash From Financing | $154.2M | $152.1M | $330.8M | $13.9M | $40.5M | |
| Free Cash Flow | -$272.6M | -$330.6M | -$401.1M | -$109M | -$133.8M | |
RXRX
Sector
Market Cap
$2B
$33.5M
Price % of 52-Week High
40.7%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
-15.61%
-0.82%
1-Year Price Total Return
-33.6%
-35.33%
Beta (5-Year)
--
0.631
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.08
200-day SMA
Sell
Level
$6.32
Bollinger Bands (100)
Sell
Level
4.33 - 7.39
Chaikin Money Flow
Sell
Level
-427.2M
20-day SMA
Buy
Level
$4.99
Relative Strength Index (RSI14)
Buy
Level
50.95
ADX Line
Buy
Level
23.14
Williams %R
Neutral
Level
-77.037
50-day SMA
Buy
Level
$4.92
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
144.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.9246)
Sell
CA Score
(Annual)
Level (-1.4542)
Buy
Beneish M-Score
(Annual)
Level (-3.3494)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.5069)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Stock Forecast FAQ
In the current month, RXRX has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The RXRX average analyst price target in the past 3 months is $7.14.
-
Where Will Recursion Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Recursion Pharmaceuticals share price will rise to $7.14 per share over the next 12 months.
-
What Do Analysts Say About Recursion Pharmaceuticals?
Analysts are divided on their view about Recursion Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Recursion Pharmaceuticals is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Recursion Pharmaceuticals's Price Target?
The price target for Recursion Pharmaceuticals over the next 1-year time period is forecast to be $7.14 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is RXRX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Recursion Pharmaceuticals is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of RXRX?
You can purchase shares of Recursion Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Recursion Pharmaceuticals shares.
-
What Is The Recursion Pharmaceuticals Share Price Today?
Recursion Pharmaceuticals was last trading at $5.03 per share. This represents the most recent stock quote for Recursion Pharmaceuticals. Yesterday, Recursion Pharmaceuticals closed at $5.03 per share.
-
How To Buy Recursion Pharmaceuticals Stock Online?
In order to purchase Recursion Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did David Tepper Sell NVIDIA Stock?
In Q1, billionaire David Tepper of Appaloosa Management sold nearly…
Why Is Planet Labs Stock Up Today?
Planet Labs (NYSE: PL) opened Friday trading with an unmistakable…
Stock Ideas
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 54x
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
49
NKE alert for Jun 28
Nike [NKE] is up 15.29% over the past day.
Buy
81
KTOS alert for Jun 28
Kratos Defense & Security Solutions [KTOS] is up 10.89% over the past day.
Sell
44
GDXU alert for Jun 28
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 10.89% over the past day.
